Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 6.9% – Here’s What Happened

Posted by Stanley Muller on Aug 7th, 2026

Marker Therapeutics, Inc. (NASDAQ:MRKR – Get Free Report) traded down 6.9% during mid-day trading on Wednesday . The stock traded as low as $1.10 and last traded at $1.1450. 103,065 shares were traded during trading, an increase of 122% from the average session volume of 46,424 shares. The stock had previously closed at $1.23.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings downgraded Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $10.00.

View Our Latest Report on MRKR

Marker Therapeutics Stock Performance

The firm has a market cap of $18.67 million, a price-to-earnings ratio of -1.84 and a beta of 1.50. The business has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.46.

Marker Therapeutics (NASDAQ:MRKR – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $0.75 million during the quarter, compared to analysts’ expectations of $0.78 million. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%. On average, equities research analysts forecast that Marker Therapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Marker Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in MRKR. NewEdge Advisors LLC purchased a new position in Marker Therapeutics during the 4th quarter valued at about $222,000. Renaissance Technologies LLC lifted its holdings in shares of Marker Therapeutics by 41.8% in the first quarter. Renaissance Technologies LLC now owns 175,294 shares of the company’s stock valued at $228,000 after purchasing an additional 51,644 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics in the fourth quarter valued at approximately $60,000. Boyer Financial Services Inc. acquired a new stake in shares of Marker Therapeutics in the fourth quarter valued at approximately $57,000. Finally, Two Sigma Investments LP purchased a new position in shares of Marker Therapeutics during the 3rd quarter worth approximately $33,000. 22.39% of the stock is currently owned by hedge funds and other institutional investors.

Marker Therapeutics Company Profile

(Get Free Report)

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.